Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Mar;55(3):348-55.
doi: 10.1136/gut.2005.074971. Epub 2005 Sep 14.

Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease

J O Lindsay  1 , K Whelan, A J Stagg, P Gobin, H O Al-Hassi, N Rayment, M A Kamm, S C Knight, A Forbes
Affiliations
Clinical Trial

Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease

J O Lindsay et al. Gut. 2006 Mar.

Abstract

Background and aims: The intestinal microbiota play a pivotal role in the inflammation associated with Crohn's disease through their interaction with the mucosal immune system. Some bifidobacteria species are immunoregulatory and induce increased dendritic cell interleukin 10 (IL-10) release in vitro. Fructo-oligosaccharides (FOS) increase faecal and mucosal bifidobacteria in healthy volunteers. The aim of this study was to assess the effect of FOS administration on disease activity, bifidobacteria concentrations, and mucosal dendritic cell function in patients with moderately active Crohn's disease.

Patients and methods: Ten patients with active ileocolonic Crohn's disease received 15 g of FOS for three weeks. Disease activity was measured using the Harvey Bradshaw index. Faecal and mucosal bifidobacteria were quantified by fluorescence in situ hybridisation, and mucosal dendritic cell IL-10 and Toll-like receptor (TLR) expression were assessed by flow cytometry of dissociated rectal biopsies.

Results: FOS induced a significant reduction in the Harvey Bradshaw index from 9.8 (SD 3.1) to 6.9 (3.4) (p<0.01). There was a significant increase in faecal bifidobacteria concentration from 8.8 (0.9) log(10) to 9.4 (0.9) log(10) cells/g dry faeces (p<0.001). The percentage of IL-10 positive dendritic cells increased from 30 (12)% to 53 (10)% (p=0.06). Finally, the percentage of dendritic cells expressing TLR2 and TLR4 increased from 1.7 (1.7)% to 36.8 (15.9)% (p=0.08) and from 3.6 (3.6)% to 75.4 (3.4)% (p<0.001), respectively.

Conclusions: FOS supplementation increases faecal bifidobacteria concentrations and modifies mucosal dendritic cell function. This novel therapeutic strategy appears to decrease Crohn's disease activity in a small open label trial and therefore warrants further investigation.

PubMed Disclaimer

References

    1. Sartor R B. Intestinal micro‐flora in human and experimental inflammatory bowel disease. Curr Opin Gastroenterol 200117324–330. - PubMed
    1. Sellon R K, Tonkonogy S, Schultz M.et al Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin‐10‐deficient mice. Infect Immun 1998665224–5231. - PMC - PubMed
    1. Swidsinski A, Ladhoff A, Pernthaler A.et al Mucosal flora in inflammatory bowel disease. Gastroenterology 200212244–54. - PubMed
    1. Harper P G, Lee E C, Kettlewell M G W.et al Role of faecal stream in the maintenance of Crohn's colitis. Gut 198526279–284. - PMC - PubMed
    1. Fasoli R, Kettlewell M G W, Mortensen N J.et al Response to fecal challenge in defunctioned colonic Crohn's disease: prediction of long term response. Br J Surg 199077616–617. - PubMed

Publication types